ThreatMetrix Winter ’18 Release Increases Speed, Accuracy and Reliability of Digital Identity Assessments
ThreatMetrix ®, The Digital Identity Company® today announced the Winter ’18 Release, which features new industry-level classifications and performance enhancements which bolster ThreatMetrix real-time solutions.
Improving Performance of the Digital Identity Network
ThreatMetrix has invested in significant upgrades across the Digital Identity Network®:
- SmartID has been re-architected to provide superior and faster cookie-less device recognition. This delivers improved global matching across the 4.5 billion unique devices on the ThreatMetrix Network.
- Improved responsiveness in the ThreatMetrix Decision Management Portal, supported by a new data warehouse and acceleration layer for reporting.
- Infrastructure investments across multiple global data centers to support resilience and peak throughput.
“ThreatMetrix has pioneered new capabilities in the digital identity space. However, we see the ongoing fine-tuning of existing technologies as equally important. This is why we have invested heavily in improving the accuracy, latency and usability of key features within the Digital Identity Network, so that our customers can get even better results; particularly in the run up to the holiday season,” says Alisdair Faulkner, chief products officer at ThreatMetrix.
Deeper Industry-Level Analysis
The new industry classification feature allows customers to derive more value from the Network at an industry level. For example, customers can compare attack rates and target metrics such as optimum review rates by industry type, as a filter within rules for fine-grained analysis during policy evaluation. This is ideal for customers who have unique reporting needs and want to benchmark performance.
The classification is a two-tier system defining a primary industry (e.g. banking) and a secondary industry within it (e.g. credit union). This feature is also useful for customers that have their own multi-level structures to classify events from each sub-organization according to its own industry type.
- New attributes have been added to enhance data modelling and support upcoming features.
- New reports have been added, including reason code analysis, top rules activated, unknown sessions and device recognition.
General Availability of New Innovations
Significant new technologies, ThreatMetrix ID™ and Smart Authentication™ were announced at the Digital Identity Summit 2017, and are now generally available to existing and new ThreatMetrix customers.
- ThreatMetrix ID: The world’s first unique, anonymous customer identifier for the 1.4 billion users on the ThreatMetrix Digital Identity Network®. This technology features an interactive graph visualization of attributes related to an individual, a confidence score on the veracity of the ID and a trust score.
- Smart Authentication: Integrated risk-based and strong authentication capabilities, featuring mobile application security, device binding, multi-factor authentication (MFA) and a range of FIDO-complaint biometrics capabilities.
“Since 2009, ThreatMetrix held a clear vision to revolutionize the way fraud and authentication decisions are made,” adds Faulkner. “We have relentlessly pursued this goal with each enhancement across our digital identity intelligence, end-to-end decision platform and integrated strong authentication capabilities. The culmination of nine years of innovation in this space is ThreatMetrix ID, the world’s first and only digital ID of its kind.”
ThreatMetrix customers can register for the Winter ’18 Release webinar on Wednesday, December 6, 2017 which will cover ThreatMetrix ID, Smart Authentication (featuring MFA Secure Notification), and core product enhancements including Smart ID3 and Industry Classification.
ThreatMetrix®, The Digital Identity Company®, empowers the global economy to grow profitably and securely without compromise. With deep insight into 1.4 billion anonymized user identities, ThreatMetrix ID™ delivers the intelligence behind 75 million daily authentication and trust decisions to differentiate legitimate customers from fraudsters in real time.
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Dole’s Joint Venture Recycling Company Celebrates 25 Years21.5.2018 14:00 | Tiedote
Dole Food Company announced today that Recyplast S.A., an innovative plastic recycling company based in Costa Rica and with joint ownership including a subsidiary of Dole Fresh Fruit, recently surpassed 25 years in its mission to dramatically reduce and reuse agricultural waste. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180521005160/en/ Raul Martinez (right), General Manager of Dole Standard Fruit de Costa Rica, receives a plaque from Jose Miguel Ramirez, General Manager of Recyplast, in recognition of the contribution of Dole's banana plantations in the correct handling, storage, and provision of field plastic waste. The plastic recycling facility pioneered the collection of field plastics after use in banana growing operations in Costa Rica. This reuse and recycling process includes reclamation of plastic bags that protect bananas from weather and insects, as well as the collection of plastic twine used to prop the ba
ViiV Healthcare Receives EU Marketing Authorisation for Juluca (dolutegravir/rilpivirine), the First 2-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIV21.5.2018 13:11 | Tiedote
ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the European Commission has granted marketing authorisation for Juluca (dolutegravir 50mg/rilpivirine 25mg) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor.1 Juluca is a 2-drug regimen of dolutegravir (ViiV Healthcare), the most widely prescribed integrase inhibitor worldwide,2 and rilpivirine (Janssen Sciences Ireland UC, part of the Janssen Pharmaceutical Companies of Johnson & Johnson).1 Deborah Waterhouse, CEO ViiV Healthcare said, “The European Commission Decision for Juluca is very positive news for people living with
Janssen Announces European Commission Approval of JULUCA®▼ (dolutegravir/rilpivirine), the First Two-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIV-121.5.2018 13:06 | Tiedote
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the European Commission has granted marketing authorisation for JULUCA® (dolutegravir 50mg [ViiV Healthcare]/rilpivirine 25mg [Janssen Sciences Ireland UC]).1 ViiV Healthcare, as the marketing authorisation holder, will market dolutegravir/rilpivirine in all countries in the European Union and European Economic Area. Dolutegravir/rilpivirine is the first two-drug regimen, once-daily, single-pill for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase inhibitor (INI).1 “The European Commission Decision for dolutegravir/rilpivirine marks a significant milestone in our 25-year commitment to make HIV history,” said Brian Woo
Chugai Presents Results of Two Pivotal Phase lll Studies for its Bispecific Antibody HEMLIBRA® at WFH 201821.5.2018 12:44 | Tiedote
Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) today announced that full results from HAVEN 3 study (NCT02847637) and HAVEN 4 study (NCT03020160) evaluating Chugai’s hemophilia A treatment HEMLIBRA® [generic name: emicizumab (genetical recombination)] are being presented at the World Federation of Hemophilia 2018 World Congress held in Glasgow, Scotland from May 20 to 24. HAVEN 3 study is conducted in people with hemophilia A without inhibitors, and HAVEN 4 study is conducted in people with hemophilia A with or without inhibitors. Results from both studies will be presented as late-breaking abstracts. “The results from HAVEN 3 study demonstrate that HEMLIBRA, which was created with Chugai’s proprietary antibody engineering technologies, can reduce the bleeding risk in people with hemophilia A without inhibitors. The intra-patient comparison in this study also shows a statistically significant reduction in bleeding by HEMLIBRA prophylaxis compared to factor VIII therapy, the current stand
STATS Unveils STATS GPS, the Most Advanced Technology for Athlete Monitoring21.5.2018 10:00 | Tiedote
Today, STATS, the worldwide leader in sports data and intelligence, unveiled STATS GPS, an innovative system that uses a revolutionary 50-Hz sampling frequency to provide the most advanced real-time GPS technology available. STATS GPS allows teams to monitor player performance with customizable metrics like accelerations/decelerations, energy expenditure, count of zone entries, and time, distance and power thresholds. The innovative solution uses real 50-Hz sampling frequency and allows practitioners to monitor up to 100 players in real-time and post session with over 300 GPS, IMU and HR derived metrics. Embedded in the GPS vests are textile heart-rate sensors, making STATS GPS the most advanced technology on the market. “Teams and conditioning coaches need the latest technology to ensure players stay at peak health and fitness during long seasons,” said Ryan Paterson, Chief Global Officer at STATS. “With STATS GPS’ new 50-Hz technology, teams can instantly get performance information,
Sofinnova Partners Appoints Dr. Martin T. Rothman as Venture Partner21.5.2018 09:00 | Tiedote
Sofinnova Partners, a leading European venture capital firm specialized in Life Sciences, has appointed Dr. Martin T. Rothman as Venture Partner. Dr. Rothman brings forty years of experience and a strong international network in the medical field to Sofinnova Partners. As Venture Partner, Dr. Rothman will focus on helping the team identify and evaluate promising medical device companies and on mentoring entrepreneurs and physicians launching clinical innovations. Sofinnova Partners and Dr. Rothman have closely collaborated over many years. Dr. Rothman is the founder of LimFlow and an independent board member of HighLife, both portfolio companies of Sofinnova Partners. Until recently, he was Vice President of medical affairs for coronary, structural heart and renal denervation for Medtronic, based in Santa Rosa (CA), a position he held since 2010. He was involved in the development of the renal denervation program, the Trans-Aortic Valve Replacement program, and the Medtronic percutaneo
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme